MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway
International Immunopharmacology · 2023-08 · 121 · 110494
DOI: 10.1016/j.intimp.2023.110494 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-08. Verfasst von Zijian Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, Ch…. Hauptthemen laut MEDLINE: Hashimoto Disease, Macrophage Migration-Inhibitory Factors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Southern Medical University, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Hashimoto's thyroiditis is a typical thyroid autoimmune disease and Th17 cells are crucial in its development. In recent years, MIF (Macrophage Migration Inhibitory Factor) has been found to promote the secretion of IL-17A and the production and differentiation of Th17 cells. However, the specific mechanism of it remains unclear. Here, we found that the expression of MIF, IL-17A and HVEM (Herpes Virus Entry Mediator) were up-regulated in HT patients. The proportion of Th17 cells in peripheral blood mononuclear cells was positively correlated with the serum MIF protein level. We further found that the expression of HVEM and the phosphorylation level of NF-κB in peripheral blood mononuclear cells of HT patients were significantly increased. Therefore, we speculated that MIF promotes Th17 cell differentiation through HVEM and NF-κB signaling pathways. Further mechanism studies showed that MIF could directly bind to HVEM, and the stimulation of rhMIF in vitro could increase the expression of HVEM and activate NF-κB signaling pathways to promote Th17 cell differentiation. After blocking HVEM with HVEM antibody, the effect of MIF on Th17 cell differentiation disappeared. The results above show that the differentiation of Th17 cells is promoted by MIF combined with HVEM through NF-κB signaling pathways. Our research provides a new theory to the regulation mechanism of Th17 cell differentiation and gives hint to new potential therapeutic targets for HT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, China.
- Department of Medical Research Center, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, China.
- Department of Medical Research Center, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, China. Electronic address: kangki@163.com.
- Department of Laboratory Medicine, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, China. Electronic address: 13883274679@139.com.
Förderung
- National Natural Science Foundation of China
- Southern Medical University
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Liu, Z., Li, Z., Yan, G., Lin, C., Luo, Y., Ye, Y., Zeng, X., & Yao, J. (2023). MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway. International Immunopharmacology, 121, 110494. https://doi.org/10.1016/j.intimp.2023.110494
Vancouver
Liu Z, Li Z, Yan G, Lin C, Luo Y, Ye Y, et al. MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway. International Immunopharmacology. 2023;121:110494. doi:10.1016/j.intimp.2023.110494
BibTeX
@article{Liu2023,
author = {Liu, Zijian and Li, Zhihao and Yan, Guozhi and Lin, Can and Luo, Yaosheng and Ye, Yanshi and Zeng, Xiaokang and Yao, Jie},
title = {MIF promotes Th17 cell differentiation in Hashimoto's thyroiditis by binding HVEM and activating NF-κB signaling pathway},
journal = {International Immunopharmacology},
year = {2023},
volume = {121},
pages = {110494},
doi = {10.1016/j.intimp.2023.110494}
}
EUVIMED